PUMA BIOTECHNOLOGY, INC. Payments to Acquire Available-for-sale Securities
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Payments to Acquire Available-for-sale Securities of $71.11 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-05.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2018-11-05
- PUMA BIOTECHNOLOGY, INC. payments to acquire available-for-sale securities for the quarter ending 2018-09-30 was $32.51M, a 15021.86% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. payments to acquire available-for-sale securities for the quarter ending 2017-12-31 was $1.00K.
- PUMA BIOTECHNOLOGY, INC. payments to acquire available-for-sale securities for the quarter ending 2017-09-30 was $215.00K, a 98.87% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. payments to acquire available-for-sale securities for the quarter ending 2017-06-30 was -$215.00K, a 100.83% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. payments to acquire available-for-sale securities for fiscal 2017 was $79.73M, a 2.52% decline from fiscal 2016.
- PUMA BIOTECHNOLOGY, INC. payments to acquire available-for-sale securities for fiscal 2016 was $81.79M, a 61.92% decline from fiscal 2015.
- PUMA BIOTECHNOLOGY, INC. payments to acquire available-for-sale securities for fiscal 2015 was $214.81M, a 62.41% increase from fiscal 2014.
- PUMA BIOTECHNOLOGY, INC. payments to acquire available-for-sale securities for fiscal 2014 was $132.26M, a 168.02% increase from fiscal 2013.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month | Payments to Acquire Available-for-sale Securities 39 month | Payments to Acquire Available-for-sale Securities 42 month | Payments to Acquire Available-for-sale Securities 45 month | Payments to Acquire Available-for-sale Securities 48 month |
|---|---|---|---|---|---|---|---|---|
| 2018-09-30 | $32.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $71.11M 10-Q · filed 2018-11-05 | ||||||
| 2018-06-30 | $38.60M 10-Q · filed 2018-08-09 | |||||||
| 2017-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $216.00K derived: sum of 2 quarters · filed 2018-11-05 | $1.00K derived: sum of 3 quarters · filed 2018-11-05 | $79.73M 10-K · filed 2018-03-09 | ||||
| 2017-09-30 | $215.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $0.00 derived: sum of 2 quarters · filed 2018-11-05 | $79.73M 10-Q · filed 2018-11-05 | $79.73M derived: sum of 4 quarters · filed 2018-11-05 | ||||
| 2017-06-30 | -$215.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $79.51M 10-Q · filed 2018-08-09 | $79.51M derived: sum of 3 quarters · filed 2018-08-09 | $98.58M derived: sum of 4 quarters · filed 2018-08-09 | ||||
| 2017-03-31 | $79.73M 10-Q · filed 2018-05-10 | $79.73M derived: sum of 2 quarters · filed 2018-05-10 | $98.80M derived: sum of 3 quarters · filed 2018-05-10 | $124.75M derived: sum of 4 quarters · filed 2018-05-10 | ||||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $19.07M derived: sum of 2 quarters · filed 2018-03-09 | $45.03M derived: sum of 3 quarters · filed 2018-03-09 | $81.79M 10-K · filed 2018-03-09 | ||||
| 2016-09-30 | $19.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $45.03M derived: sum of 2 quarters · filed 2017-11-09 | $81.79M 10-Q · filed 2017-11-09 | $84.82M derived: sum of 4 quarters · filed 2018-03-09 | ||||
| 2016-06-30 | $25.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $62.73M 10-Q · filed 2017-08-09 | $65.75M derived: sum of 3 quarters · filed 2018-03-09 | $90.81M derived: sum of 4 quarters · filed 2018-03-09 | ||||
| 2016-03-31 | $36.77M 10-Q · filed 2017-05-10 | $39.79M derived: sum of 2 quarters · filed 2018-03-09 | $64.85M derived: sum of 3 quarters · filed 2018-03-09 | $146.74M derived: sum of 4 quarters · filed 2018-03-09 | ||||
| 2015-12-31 | $3.02M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $28.09M derived: sum of 2 quarters · filed 2018-03-09 | $109.97M derived: sum of 3 quarters · filed 2018-03-09 | $214.81M 10-K · filed 2018-03-09 | ||||
| 2015-09-30 | $25.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $106.94M derived: sum of 2 quarters · filed 2016-11-09 | $211.78M 10-Q · filed 2016-11-09 | $211.78M derived: sum of 4 quarters · filed 2017-03-01 | ||||
| 2015-06-30 | $81.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $186.72M 10-Q · filed 2016-08-09 | $186.72M derived: sum of 3 quarters · filed 2017-03-01 | $193.46M derived: sum of 4 quarters · filed 2017-03-01 | ||||
| 2015-03-31 | $104.84M 10-Q · filed 2016-05-10 | $104.84M derived: sum of 2 quarters · filed 2017-03-01 | $111.58M derived: sum of 3 quarters · filed 2017-03-01 | |||||
| 2014-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $6.74M derived: sum of 2 quarters · filed 2017-03-01 | $132.26M 10-K · filed 2017-03-01 | |||||
| 2014-09-30 | $6.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $132.26M 10-Q · filed 2015-11-09 | $181.61M 10-Q · filed 2014-11-10 | |||||
| 2014-06-30 | $125.52M 10-Q · filed 2015-08-10 | $174.87M 10-Q · filed 2014-08-11 | ||||||
| 2014-03-31 | $0.00 derived: 10-Q 42 month − 10-K 39 month · filed 2014-05-12 | $4.96M derived: sum of 2 quarters · filed 2016-02-29 | $2.65M derived: sum of 3 quarters · filed 2016-02-29 | $22.25M derived: sum of 4 quarters · filed 2016-02-29 | $49.35M 10-Q · filed 2014-05-12 | |||
| 2013-12-31 | $4.96M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $2.65M derived: sum of 2 quarters · filed 2016-02-29 | $22.25M derived: sum of 3 quarters · filed 2016-02-29 | $49.35M 10-K · filed 2016-02-29 | $49.35M 10-K · filed 2014-03-03 | |||
| 2013-09-30 | -$2.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $17.29M derived: sum of 2 quarters · filed 2014-11-10 | $44.38M 10-Q · filed 2014-11-10 | |||||
| 2013-06-30 | $19.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $46.69M 10-Q · filed 2014-08-11 | ||||||
| 2013-03-31 | $27.09M 10-Q · filed 2014-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |